Although the combination use of lenvatinib plus pembrolizumab did not induce statistically significant differences in the co-primary end points, the LEAP-002 trial induced the longest seen median overall survival with lenvatinib monotherapy in patients with unresectable HCC.
Read More
Dalpiciclib Improves PFS in the First-Line for HR+/HER2– Advanced Breast Cancer
September 9th 2022The phase 2 DAWNA-2 trial of dalpiciclib plus letrozole or anastrozole led to a reduced the risk of disease progression vs chemotherapy alone in patients with treatment-naïve, hormone receptor–positive, HER2-negative advanced breast cancer.
Read More
CLDN6 CAR T-Cell Therapy Elicits Clinical Activity in Relapsed/Refractory Advanced Solid Tumors
September 9th 2022The investigational carcinoembryonic antigen claudin 6–directed CAR T-cell therapy BNT211-01 displayed clinical activity in combination with a CLDN6-encoding mRNA vaccine in patients with CLDN6-positive relapsed/refractory advanced solid tumors.
Read More
Adding Oleclumab to Durvalumab and Chemotherapy Does Not Reach Clinical Benefit in Advanced TNBC
September 9th 2022Oleclumab plus durvalumab and chemotherapy did not increase clinical benefit rate for patients with advanced triple-negative breast cancer, according to results from the phase 2 SYNERGY trial.
Read More
Sactiuzumab Govitecan Significantly Improves OS in Pretreated HR+/HER2- Metastatic Breast Cancer
September 9th 2022Treatment with sactiuzumab govitecan improved overall survival, objective response rate, duration of response, and overall quality of life vs physician’s choice in the phase 3 TROPiCS-02 study.
Read More
Promising Safety and Efficacy Seen With Higher-Dose Rhenium-186 Nanoliposome in Recurrent Glioma
September 9th 2022Rhenium-186 nanoliposome at doses exceeding 100 Gy showed promising results in patients with recurrent glioma, according to phase 1 findings from the ReSPECT-GBM trial presented at ESMO 2022.
Read More
Abemaciclib Plus Aromatase Inhibitors Shows Improved OS in HR+/HER2- Breast Cancer
September 9th 2022Updated findings of the MONARCH 3 trial of abemaciclib added to a nonsteroidal aromatase inhibitor presented at ESMO 2022 revealed prolonged overall survival in hormone receptor-positive, HER2-negative breast cancer.
Read More
Dara-RVd Reduces Risk of Progression or Death in Transplant-Eligible NDMM
August 28th 2022The combination of daratumumab plus lenalidomide, bortezomib, and dexamethasone continued to show superior efficacy in patients with newly diagnosed multiple myeloma based on the GRIFFIN trial's final analysis reported at the 19th International Myeloma Society annual meeting.
Read More
Carfilzomib Plus Lenalidomide/Dexamethasone After Transplant Extends PFS Over Lenalidomide in MM
August 26th 2022Data presented at the 19th International Myeloma Society Annual Meeting show that carfilzomib plus lenalidomide and dexamethasone after transplant prolongs progression-free survival compared with lenalidomide alone in patients with myeloma.
Read More
Daratumumab Plus Lenalidomide/Dexamethasone Prolong OS When Administered Long-Term in Myeloma
August 26th 2022Patients with treatment-naive myeloma treated with humanized IgGx CD38-targeted monoclonal antibody daratumumab in combination with lenalidomide and dexamethasone for at least 18 months had a overall survival benefit in the phase 3 MAIA study.
Read More
Isa-Kd Maintains Long-Term PFS Benefit in Relapsed Multiple Myeloma
August 26th 2022Updated analysis of the IKEMA trial showed the combination of isatuximab, carfilzomib, and dexamethasone to elicit superior progression-free survival vs carfilzomib and dexamethasone alone in patients with multiple myeloma.
Read More